Revolutionary Advancements in Induced Pluripotent Stem Cell (iPSC) Industry: A Comprehensive Report on Market Dynamics, Trends and Forecasts to 2030 - ResearchAndMarkets.com

The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development. It covers the current status of iPSC research, biomedical applications, manufacturing technologies, patents, and funding events, as well as all known trials for the development of iPSC-derived cell therapeutics worldwide.

Importantly, it profiles leading market competitors worldwide and presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type, and Geography (North America, Europe, Asia/Pacific, and Rest of World). It also presents total market size figures with projected growth rates through 2030.

Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. iPSCs can be used to explore the causes of disease onset and progression, create and test new drugs and therapies, and treat previously incurable diseases.

Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:

• Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
• Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models "in a dish".
• Drug Development and Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
• Personalized Medicine: The use of techniques such as CRISPR enable precise, directed creation of knock-outs and knock-ins (including single base changes) in many cell types. Pairing iPSCs with genome editing technologies is adding a new dimension to personalized medicine.
• Toxicology Testing: iPSCs can be used for toxicology screening, which is the use of iPSCs or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
• Tissue Engineering: iPSCs can be seeded onto scaffolds made from biocompatible materials. These scaffolds mimic the structure and properties of the target tissue and can provide a supportive environment for cell growth and differentiation.
• Organoid Production: iPS cells can be coaxed to self-organize into 3D structures called organoids, which mimic the structure and function of organs. Organoids can be used for studying organ development, modeling diseases, and testing drugs.
• Gene Editing: iPS cells can be genetically modified using techniques like CRISPR-Cas9 to correct disease-causing mutations or introduce specific genetic changes. These edited iPS cells can then be differentiated into the desired cell type for transplantation or disease modeling.
• Research Tools: iPSCs and iPSC-derived cell types are being widely used within a diverse range of basic and applied research applications.
• Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.
• Cultured Meat Production: iPSCs are being utilized in clean meat production by serving as the cellular foundation for the creation of lab-grown meat.
• 3D Bioprinting: iPSCs can be directed to differentiate into cell types of interest, such as skin, heart, or liver cells, which are then incorporated into bioinks.
• Wildlife Conservation and De-extinction Projects: iPSCs are being used in wildlife conservation and de-extinction projects. For example, Colossal Biosciences is using iPSC technology in an effort to achieve woolly mammoth de-extinction.

Key Topics Covered:

1. REPORT OVERVIEW

2. INTRODUCTION

3. CURRENT STATUS OF IPSC INDUSTRY

3.1 Progress made in Autologous Cell Therapy using iPSCs

3.2 Allogeneic iPSC-based Cell Therapies

3.3 Share of iPSC-based Research within the Overall Stem Cell Industry

3.4 Major Focus Areas of iPSC Companies

3.5 Commercially Available iPSC-derived Cell Types

3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays

3.7 iPSC-derived Cell Types used in Clinical Trials

3.8 Currently Available iPSC Technologies

• Nucleofector Technology
• Opti-ox Technology
• MOGRIFY Technology
• Transcription Factor-based iPSC Differentiation Technology
• Flowfect Technology
• Technology for Mass Production of Platelets
• SynFire Technology

4. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

5. RESEARCH PUBLICATIONS ON IPSCS

6. IPSC: PATENT LANDSCAPE ANALYSIS

6.1 iPSC Patent Applications by Jurisdiction

6.2 iPSC Patent Applicants

6.3 Inventors of iPSC Patents

6.4 iPSC Patent Owners

6.5 Legal Status of iPSC Patents

7. IPSC: CLINICAL TRIAL LANDSCAPE

7.1 Number of iPSC Clinical Trials

7.2 Recruitment Status of iPSC Clinical Trials

7.3 iPSC Clinical Trials Study Designs

7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials

7.5 iPSC-based Trials by Phase of Study

7.6 iPSC Clinical Trials by Funder Type

7.7 Geographic Distribution of iPSC-based Clinical Trials

7.8 Promising iPSC Product Candidates

• CYP-001, CYP-004 & CYP-006 from Cynata Therapeutics
• BioVAT-HF from Repairon GmbH
• HS-001 from Heartseed
• CNTY-101 from Century Therapeutics
• FT-576 & FT-819 from Fate Therapeutics
• RPE from National Eye Institute
• QN-019a from Qihan Biotech
• iPSC-CL from Heartworks, Inc.

7.9 Companies having Preclinical iPSC Assets

• Aspen Neuroscience
• Ryne Biotech
• Bluerock Therapeutics
• Vita Therapeutics
• Hopstem Biotechnology
• Res Nova Bio, Inc.
• Cytovia Therapeutics
• Hebecell Corporation
• Sana Biotechnology
• SCG Cell Therapy Pte
• Cytomed
• Shoreline Biosciences
• Neukio Biotherapeutics
• Exacis Biotherapeutics
• CellOrigin Biotech

8. M&A, COLLABORATIONS & FUNDING ACTIVITIES IN IPSC SECTOR

8.1 Mergers and Acquisitions (M&A) Sector

• Century Therapeutics & Clade Therapeutics
• Evotech & Rigenerand
• Fujifilm Corporation & Atara Biotherapeutics
• Catalent & RheinCell Therapeutics
• Axol Biosciences & Censo Biotechnologies
• Bayer AG & Bluerock Therapeutics
• Pluriomix & Axiogenesis

8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector

• Shinobi Therapeutics & Panasonic
• SCG Cell Therapy and A*STAR
• Charles River Laboratories & Pluristyx, Inc.
• Pluristyx, Inc. & National Resilience, Inc.
• University of Texas & GeneCure
• Heartseed, Inc. & Undisclosed Biotech
• Bluerock Therapeutics & Bit.bio
• Applied Stem Cell, Inc. & CIRM
• Resolution Therapeutics & OmniaBio, Inc.
• REPROCELL, Inc. & CIRM
• REPROCELL, Inc. & BioBridge Global
• Elevate Bio & CIRM
• Evotec & Sernova
• Evotec & Almiral
• Quell Therapeutics & Cellistic
• MDimmune & YiPSCELL
• Edigene & Neukio Biotherapeutics
• Matricelf & Ramot
• Evotec & Boehringer Ingelheim
• Pluristyx, Pancella & Implant Therapeutics
• Century Therapeutics & Bristol Myers Squibb
• Fujifilm Cellular Dynamics & Pheno Vista Biosciences
• Metrion Biosciences & Bioqube Ventures
• Cytovia Therapeutics & Cellectis
• Exacis Biotherapeutics & CCRM
• Cynata Therapeutics & Fujifilm Corporation
• Bone Therapeutics & Implant Therapeutics
• REPROCELL & TEXCELL
• Jacobio & Herbecell
• NeuCyte & KIF1A.ORG
• Kite & Shoreline Biosciences
• Neuropath Therapeutics & Hopstem Biotechnology
• Allele Biotech & Cellatoz
• Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics
• Newcells & Takeda
• Biocentriq & Kytopen
• Fujifilm Cellular Dynamics & Sana Biotechnology
• Evotec & Medical Center Hamburg-Eppdorf (UKE)
• NeuCyte & Seaver Autism Center for Research and Treatment
• Cytovia Therapeutics & National Cancer Institute
• Mogrify & MRC Laboratory of Molecular Biology

8.3 Venture Capital Funding in iPSC Sector

• Asgard Therapeutics
• Kenai Therapeutics
• Pluristyx
• Fujifilm Cellular Dynamics
• Mogrify Ltd.
• Heartseed, Inc.
• Elevate Bio
• Aspen Neurosciences
• Axol Biosciences
• Thyas, Co. Ltd
• Synthego
• Cellino Biotech, Inc
• Curi Bio
• Ncardia
• Evotec SE
• bit.bio
• Clade Therapeutics
• Shoreline Biosciences
• Kytopen
• Cytovia Therapeutics & CytoLynx
• TreeFrog Therapeutics
• HebeCell Corporation
• Neukio Biotherapeutics
• Stemson Therapeutics
• Vita Therapeutics
• Century Therapeutics
• Heartseed
• Mogrify
• Metrion Biosciences
• Elevate Bio
• Vita Therapeutics

9. GENERATION OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)

9.1 OSKM Cocktail

9.2 Pluripotency-Associated Transcription Factors and their Functions

9.3 Delivery of Reprogramming Factors

9.3.1 Integrating Systems

9.3.2 Non-Integrative Delivery Systems

9.3.3 Comparison of Delivery Methods

9.4 Genome Editing Technologies in iPSC Generation

9.5 Available iPSC Lines and their applications

10. HUMAN IPSC BANKING

10.1 Major Biobanks Storing iPSCs & iPSC Lines

10.1.1 RIKEN

10.1.2 WiCell

10.1.3 Fujifilm Cellular Dynamics, Inc.

10.1.4 Sampled

10.1.5 Coriell Institute for Medical Research

10.1.6 European Bank for Induced Pluripotent Stem Cells (EBiSC)

10.2 Cell Sources for iPSC Banks

10.3 Reprogramming Methods in iPSC Banks

10.4 Ownership and Investments made in iPSC Banks

11. BIOMEDICAL APPLICATIONS OF IPSCs

11.1 iPSCs in Basic Research

11.2 Applications of iPSCs in Drug Discovery

11.3 Applications of iPSCs in Toxicology Studies

11.4 Applications of iPSCs in Disease Modeling

11.5 Applications of iPSCs in Cell-Based Therapies

11.6 Other Novel Applications of iPSCs

12. MARKET ANALYSIS

12.1 Global Market for iPSCs by Geography

12.2 Global Market for iPSCs by Technology

12.3 Global Market for iPSCs by Biomedical Application

12.4 Global Market for iPSCs by Derived Cell Type

12.5 Market Drivers

12.5.1 Current Drivers Impacting the iPSC Market Place

12.6 Market Restraints

13. COMPANY PROFILES

For more information about this report visit https://www.researchandmarkets.com/r/pf57qx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240822249608/en/